期刊
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
卷 2020, 期 -, 页码 -出版社
HINDAWI LTD
DOI: 10.1155/2020/2315106
关键词
-
类别
资金
- Project of Administration of Traditional Chinese Medicine of Guangdong Province of China [20190408212815]
Alzheimer's disease (AD) is the most common neurodegenerative disease. The accumulation of amyloid beta (A beta) is the main pathology of AD. Metformin, a well-known antidiabetic drug, has been reported to have AD-protective effect. However, the mechanism is still unclear. In this study, we tried to figure out whether metformin could activate insulin-degrading enzyme (IDE) to ameliorate A beta-induced pathology. Morris water maze and Y-maze results indicated that metformin could improve the learning and memory ability in APP(swe)/PS1(dE9) (APP/PS1) transgenic mice. F-18-FDG PET-CT result showed that metformin could ameliorate the neural dysfunction in APP/PS1 transgenic mice. PCR analysis showed that metformin could effectively improve the mRNA expression level of nerve and synapse-related genes (Syp, Ngf, and Bdnf) in the brain. Metformin decreased oxidative stress (malondialdehyde and superoxide dismutase) and neuroinflammation (IL-1 beta and IL-6) in APP/PS1 mice. In addition, metformin obviously reduced the A beta level in the brain of APP/PS1 mice. Metformin did not affect the enzyme activities and mRNA expression levels of A beta-related secretases (ADAM10, BACE1, and PS1). Meanwhile, metformin also did not affect the mRNA expression levels of A beta-related transporters (LRP1 and RAGE). Metformin increased the protein levels of p-AMPK and IDE in the brain of APP/PS1 mice, which might be the key mechanism of metformin on AD. In conclusion, the well-known antidiabetic drug, metformin, could be a promising drug for AD treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据